- |||||||||| VGX-1027 / GeneOne
Journal, IO biomarker: Free light chains injure proximal tubule cells through STAT1-HMGB1-TLR axis. (Pubmed Central) - May 22, 2021 Countering TLR2, TLR4, and TLR6 through GIT-27 or specific TLR siRNAs reduced downstream cytokine responses...PTCs exposed to FLCs released HMGB1, which induced TLRs 2, 4, 6 expression and downstream inflammation. Blocking FLCs' endocytosis, Stat1 knock-down, HMGB1 inhibition, and TLR knock-down each rescued PTCs from FLC-induced injury.
- |||||||||| INO-6145 / Inovio, PENNVAX-GP (HIV DNA vaccine) / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Trial completion, Trial completion date, Trial primary completion date: Therapeutic Vaccination in Treated HIV Disease (clinicaltrials.gov) - May 19, 2021 P1/2, N=56, Completed, Blocking FLCs' endocytosis, Stat1 knock-down, HMGB1 inhibition, and TLR knock-down each rescued PTCs from FLC-induced injury. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> May 2021 | Trial primary completion date: Dec 2021 --> May 2021
- |||||||||| VGX-1027 / GeneOne
Preclinical, Journal: Interleukin-1 beta induces autophagy of mouse preimplantation embryos and improves blastocyst quality. (Pubmed Central) - May 11, 2021 Effects of IL-1β on the development of embryo reduced in 20 ng/mL IL-1β supplemented group when 5 mM 3-methyladenine (3-MA) was also added, which used to inhibit autophagy activation in endogenous PtdIns3Ks signal pathway. Our current results show that exogenous IL-1β can effectively induce autophagy in mouse embryos at stages of 2 to 8 cell and blastocyst, that also help to improve the quality of blastocyst.
- |||||||||| INO-4800 / Inovio, The Wistar Institute
[VIRTUAL] AAV6-Mediated hACE2 Expression as a Versatile Model for SARS-CoV-2 Infection and synDNA Vaccine Efficacy () - Apr 30, 2021 - Abstract #ASGCT2021ASGCT_748; P1, P1/2 We developed a DNA vaccine encoding the SARS-CoV-2 spike glycoprotein (INO-4800) which has since entered clinical trials (NCT04336410, NCT04447781)...Finally, using antibody depletion confirmed that CD8+ effector cells play an important role in protection from challenge in this model. These data demonstrate that spike-encoding DNA vaccines are immunogenic and protective in vivo, support the continued translation of these constructs to the clinic, and demonstrate that the hAAV6-ACE2 mouse transduction model represents an easily accessible, versatile small-animal model for wild-type SARS-CoV-2 infection which can be used to evaluate anti-SARS-CoV-2 vaccine efficacy.
- |||||||||| INO-4800 / Inovio, The Wistar Institute
INO-4800 (Twitter) - Apr 28, 2021
- |||||||||| MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients (clinicaltrials.gov) - Apr 22, 2021 P2, N=0, Withdrawn, Active, not recruiting --> Completed N=66 --> 0 | Trial completion date: Sep 2027 --> Mar 2021 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2024 --> Mar 2021
- |||||||||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment open, Combination therapy: INO 5401 Vaccination in BRCA1/2 Mutation Carriers (clinicaltrials.gov) - Apr 22, 2021 P1b, N=44, Recruiting, N=66 --> 0 | Trial completion date: Sep 2027 --> Mar 2021 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2024 --> Mar 2021 Not yet recruiting --> Recruiting
- |||||||||| INO-A002 / Inovio
Trial completion date, Trial primary completion date: A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) - Mar 11, 2021 P1, N=24, Active, not recruiting, Not yet recruiting --> Recruiting Trial completion date: Feb 2021 --> Feb 2023 | Trial primary completion date: Feb 2021 --> Feb 2023
- |||||||||| bizalimogene ralaplasmid (VGX-3100) / Inovio
Trial completion date, Trial primary completion date: VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov) - Feb 25, 2021 P2, N=80, Recruiting, Trial completion date: Feb 2021 --> Feb 2023 | Trial primary completion date: Feb 2021 --> Feb 2023 Trial completion date: Sep 2021 --> Aug 2022 | Trial primary completion date: Jan 2021 --> Aug 2022
- |||||||||| INO-4800 / Inovio, The Wistar Institute
Enrollment closed, Enrollment change: INNOVATE: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure (clinicaltrials.gov) - Feb 21, 2021 P2/3, N=401, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=6578 --> 401
- |||||||||| INO-6145 / Inovio, PENNVAX-GP (HIV DNA vaccine) / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
Enrollment closed: Therapeutic Vaccination in Treated HIV Disease (clinicaltrials.gov) - Feb 12, 2021 P1/2, N=56, Active, not recruiting, Adjuvant MEDI0457 is safe and well-tolerated after chemoradiation for locally advanced and/or recurrent cervical cancers supporting further investigation into combining tumor-specific vaccines with radiotherapy. Recruiting --> Active, not recruiting
- |||||||||| INO-4800 / Inovio, The Wistar Institute, mRNA-1273 / Moderna, Takeda
Clinical, Review, Journal: The COVID-19 puzzle: a global nightmare. (Pubmed Central) - Feb 9, 2021 Recent studies have revealed any attractive vaccine candidates as promising therapeutic agents based on different strategies of vaccines. Here, the rationale of this review was also to provide an overview of the pathogenesis of the virus and summarize the updated potential vaccine candidates against SARS-CoV-2.
|